Company news
Nuvo Pharmaceuticals Inc news
Latest news releases, newest first. Pick a year for every news release, call and deck from that year.
Nuvo Pharmaceuticals(TM) Inc. Announces Results from European Ankle Sprain Study with Pennsaid® 2%
March 7, 2016
Nuvo Research® Inc. Completes Reorganization into Two Publicly Traded Companies
March 1, 2016
Nuvo Research® Inc. Obtains Final Court Order Approving Reorganization into Two Publicly-Traded Companies
February 24, 2016
Nuvo Research® Shareholders Approve Proposed Reorganization into Two Separate Public Companies
February 18, 2016
Nuvo Research® Announces 2015 Fourth Quarter & Year-End Results
February 17, 2016
Nuvo Research® and Horizon Pharma plc Extend Term of Manufacturing Agreement
February 8, 2016
Nuvo Research® Provides Estimated Revenue for the 2015 Fourth Quarter and Year End
January 21, 2016
Nuvo Research® Reacquires Pliaglis North American Development and Marketing Rights
December 22, 2015
Nuvo Research® Reports Topline Results of Phase 2 Trial of WF10(TM) for the Treatment of Allergic Rhinitis
December 21, 2015
Nuvo Research® Announces Special Shareholder Meeting to Vote on Reorganization of Nuvo into Two Publicly Traded Companies
December 15, 2015
Nuvo Research® Provides Update on Pennsaid® 2% Phase 3 Clinical Trial
December 3, 2015
Nuvo Research® Announces Acceleration of Expiry Date of Outstanding Warrants
November 30, 2015
Nuvo Research® Announces TSX Conditional Approval to List Crescita Therapeutics Inc.
November 23, 2015
Nuvo Research® Announces 2015 Third Quarter Results
November 10, 2015
Nuvo Research Announces Successful Pennsaid®2% Phase 3 Trial for Russia
November 5, 2015
Nuvo Research® Announces Appointment to its Board of Directors
November 3, 2015
Nuvo Research® Announces Intention to Split Into Two Publicly Traded Companies
September 15, 2015
Nuvo Research® Announces U.S. Patent for Topical Foamed Formulations that Include DMSO
August 20, 2015
Nuvo Research® Announces Grant of United States Patent for Topical Onychomycosis Formulation
August 11, 2015
Nuvo Research® Announces 2015 Second Quarter Results
August 5, 2015
Nuvo Research® Provides Update on International Licensing of Pennsaid® 2%
June 24, 2015
Nuvo Research® Receives Health Canada Approval to Conduct New WF10(TM) Phase 2 Trial
June 8, 2015
Nuvo Research announces director election results of its Annual General Meeting
May 13, 2015
Nuvo Research® Announces 2015 First Quarter Results
May 12, 2015
Nuvo Research® Announces New WF10(TM) Phase 2 Trial
April 22, 2015
Nuvo Research® Updates Company Strategy
April 16, 2015
Nuvo Research® Provides Business Update
March 5, 2015
Nuvo Research® Announces 2014 Fourth Quarter & Year-End Results
February 19, 2015
Nuvo Research® Reports Topline Results of Phase 2 Study of WF10(TM) for the Treatment of Allergic Rhinitis
January 30, 2015
Nuvo Research® Granted Additional U.S. Patent for Treatment of Allergic Rhinitis with WF10(TM)
December 22, 2014
Nuvo Research® reports that all patients have completed Phase 2 study of WF10(TM) for the treatment of allergic rhinitis
December 18, 2014
Nuvo Research® reacquires Pennsaid® 2% rights to South America, Central America, South Africa and Israel
November 13, 2014
Nuvo Research® Announces 2014 Third Quarter Results
November 10, 2014
Nuvo Research® plans Phase 3 study of Pennsaid® 2% to support international regulatory approvals
November 3, 2014
Nuvo Research® Completes WF10(TM) U.S. Market Study for Treatment of Refractory Allergies
October 22, 2014
Nuvo Research® Sells PENNSAID® 2% U.S. Rights for US$45 Million to Horizon Pharma
October 17, 2014
Nuvo Research® settles litigation with Mallinckrodt Pharmaceuticals
September 8, 2014
Nuvo Research® to Present at Rodman & Renshaw 16th Annual Global Investment Conference
September 4, 2014
Nuvo Research® Completes Enrolment in WF10(TM) Phase 2 Clinical Trial
September 3, 2014
Nuvo Research® announces 2014 second quarter results
July 30, 2014
Nuvo Research to present at Bloom Burton & Co Healthcare Investor Conference
June 17, 2014
Nuvo Research announces director election results of its annual general meeting
June 11, 2014
Nuvo Research® announces U.S. FDA approval of third-party generic of PENNSAID 1.5%
May 29, 2014
Nuvo Research® announces 2014 first quarter results
April 30, 2014
Nuvo Research Announces Collaboration to Develop Topical Dermatology Products
April 23, 2014
Nuvo Research® closes $3.1 million private placement
April 1, 2014
Nuvo Research announces 2013 fourth quarter & year-end results
February 20, 2014
Nuvo Research Announces the U.S. Commercial Launch of PENNSAID® 2% by Mallinckrodt
February 10, 2014
Nuvo Research Announces FDA Approval of PENNSAID® 2%
January 17, 2014
Nuvo Research® and NovaMedica sign agreement to market Pennsaid® in Russia
December 19, 2013